去氧皮质酮检测

检测范围

• 血清去氧皮质酮检测
• 血浆去氧皮质酮检测
• 尿液去氧皮质酮检测
• 唾液去氧皮质酮检测
• 醋酸去氧皮质酮原料药检测
• 醋酸去氧皮质酮注射液检测
• 去氧皮质酮片剂检测
• 去氧皮质酮胶囊检测
• 去氧皮质酮溶液剂检测
• 去氧皮质酮软膏剂检测
• 去氧皮质酮游离态检测
• 去氧皮质酮结合态检测
• 去氧皮质酮标准品检测
• 去氧皮质酮代谢物检测
• 肾上腺组织去氧皮质酮检测
• 胎盘组织去氧皮质酮检测
• 动物血清去氧皮质酮检测
• 动物尿液去氧皮质酮检测
• 去氧皮质醇与去氧皮质酮比值检测
• 新生儿足跟血去氧皮质酮检测
• 孕妇血清去氧皮质酮检测
• 去氧皮质酮同位素标记物检测

检测标准（部分）

• HG/T 6343-2024 4-氯甲基-5-甲基-1,3-二氧杂环戊烯-2-酮
• 农业部2086号公告-5-2014 饲料中卡巴氧、乙酰甲喹、喹烯酮和喹乙醇的测定液相色谱-串联质谱法
• ASTM F3384-21(2026) Standard Specification for Polydioxanone Polymer Resins for Surgical Implants
• 32010D0759 2010/759/EU: Council Decision of 2 December 2010 on submitting 4-methylmethcathinone (mephedrone) to control measures
• ASTM F3384-21 Standard Specification for Polydioxanone Polymer Resins for Surgical Implants
• AS 2508.5.005-1992 Safe storage and handling information card - Methyl ethyl ketone peroxide (MEKP) (not more than 50% in solution with not more than 10% available oxygen)
• 32016R1902 Commission Regulation (EU) 2016/1902 of 27 October 2016 amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for acetamiprid, ametoctradin, azoxystrobin, cyfluthrin, difluoroacetic acid, dimethomorph, fenpyrazamine, flonicamid, fluazinam, fludioxonil, flupyradifurone, flutriafol, fluxapyroxad, metconazole, proquinazid, prothioconazole, pyriproxyfen, spirodiclofe
• 32009R1050 Commission Regulation (EC) No 1050/2009 of 28 October 2009 amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for azoxystrobin, acetamiprid, clomazone, cyflufenamid, emamectin benzoate, famoxadone, fenbutatin oxide, flufenoxuron, fluopicolide, indoxacarb, ioxynil, mepanipyrim, prothioconazole, pyridalyl, thiacloprid and trifloxystrobin in or on certain product
• 32013R0777 Commission Regulation (EU) No 777/2013 of 12 August 2013 amending Annexes II, III and V to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for clodinafop, clomazone, diuron, ethalfluralin, ioxynil, iprovalicarb, maleic hydrazide, mepanipyrim, metconazole, prosulfocarb and tepraloxydim in or on certain products Text with EEA relevance
• 32018R0832 Commission Regulation (EU) 2018/832 of 5 June 2018 amending Annexes II, III and V to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for cyantraniliprole, cymoxanil, deltamethrin, difenoconazole, fenamidone, flubendiamide, fluopicolide, folpet, fosetyl, mandestrobin, mepiquat, metazachlor, propamocarb, propargite, pyrimethanil, sulfoxaflor and trifloxystrobin in or on certain products (T
• 32015R0399 Commission Regulation (EU) 2015/399 of 25 February 2015 amending Annexes II, III and V to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for 1,4-dimethylnaphthalene, benfuracarb, carbofuran, carbosulfan, ethephon, fenamidone, fenvalerate, fenhexamid, furathiocarb, imazapyr, malathion, picoxystrobin, spirotetramat, tepraloxydim and trifloxystrobin in or on certain products Text with EEA
• 32016R0486 Commission Regulation (EU) 2016/486 of 29 March 2016 amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for cyazofamid, cycloxydim, difluoroacetic acid, fenoxycarb, flumetralin, fluopicolide, flupyradifurone, fluxapyroxad, kresoxim-methyl, mandestrobin, mepanipyrim, metalaxyl-M, pendimethalin and tefluthrin in or on certain products (Text with EEA relevance)
• 32016R0567 Commission Regulation (EU) 2016/567 of 6 April 2016 amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for chlorantraniliprole, cyflumetofen, cyprodinil, dimethomorph, dithiocarbamates, fenamidone, fluopyram, flutolanil, imazamox, metrafenone, myclobutanil, propiconazole, sedaxane and spirodiclofen in or on certain products (Text with EEA relevance)
• 32007L0076 Commission Directive 2007/76/EC of 20 December 2007 amending Council Directive 91/414/EEC to include fludioxonil, clomazone and prosulfocarb as active substances (Text with EEA relevance )
• 32009R1050R(01) Corrigendum to Commission Regulation (EC) No 1050/2009 of 28 October 2009 amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for azoxystrobin, acetamiprid, clomazone, cyflufenamid, emamectin benzoate, famoxadone, fenbutatin oxide, flufenoxuron, fluopicolide, indoxacarb, ioxynil, mepanipyrim, prothioconazole, pyridalyl, thiacloprid and trifloxystrobin in or on
• 32016R1015 Commission Regulation (EU) 2016/1015 of 17 June 2016 amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for 1-naphthylacetamide, 1-naphthylacetic acid, chloridazon, fluazifop-P, fuberidazole, mepiquat and tralkoxydim in or on certain products (Text with EEA relevance)
• 32018R1266 Commission Implementing Regulation (EU) 2018/1266 of 20 September 2018 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, azadirachtin, bupirimate, carboxin, clethodim, cycloxydim, dazomet, diclofop, dithianon, dodine, fenazaquin, fluometuron, flutriafol, hexythiazox, hymexazol, indolylbutyric acid, isoxaben, lime sulphur, metal
• 32019R0291 Commission Implementing Regulation (EU) 2019/291 of 19 February 2019 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1-naphthylacetamide, 1-naphthylacetic acid, acrinathrin, azoxystrobin, fluazifop p, fluroxypyr, imazalil, kresoxim-methyl, oxyfluorfen, prochloraz, prohexadione, spiroxamine, tefluthrin and terbuthylazine (Text with EEA relevance.)
• 32002D0658 2002/658/EC: Commission Decision of 14 August 2002 allowing Member States to extend provisional authorisations granted for the new active substances benzoic acid, carvone, mepanipyrim, oxadiargyl and trifloxystrobin (Text with EEA relevance) (notified under document number C(2002) 3048)
• 32012R0823 Commission Regulation (EU) No 823/2012 of 14 September 2012 derogating from Implementing Regulation (EU) No 540/2011 as regards the expiry dates of the approval of the active substances 2,4-DB, benzoic acid, beta-cyfluthrin, carfentrazone ethyl, Coniothyrium minitans Strain CON/M/91-08 (DSM 9660), cyazofamid, cyfluthrin, deltamethrin, dimethenamid-P, ethofumesate, ethoxysulfuron, fenamidone, flazasulfuron, flufenacet, flurtamone, foramsulfuron, f

检测项目

• 去氧皮质酮含量测定——用于评估样品中去氧皮质酮的实际浓度，是质量控制和诊断的核心指标
• 去氧皮质酮纯度分析——判定原料药中去氧皮质酮的纯度等级，确保符合药典规定限度
• 有关物质检测——识别去氧皮质酮样品中的杂质种类和含量，控制产品质量安全
• 去氧皮质酮定性鉴别——通过特征光谱或质谱行为确认样品中是否含有去氧皮质酮成分
• 去氧皮质酮定量限测定——确定检测方法能准确定量的很低浓度，反映方法灵敏度
• 去氧皮质酮检出限测定——确定检测方法能检出的很低浓度，评估方法检测能力
• 线性范围验证——考察去氧皮质酮浓度与检测响应值之间的线性关系，确保定量准确
• 回收率测试——评估检测方法在添加已知浓度去氧皮质酮后的回收程度，验证方法准确性
• 精密度测试——通过重复测定去氧皮质酮样品考察方法的重复性和重现性
• 去氧皮质酮稳定性考察——评估去氧皮质酮在不同温度和光照条件下的化学稳定性
• 去氧皮质酮代谢产物分析——检测去氧皮质酮在生物体内的代谢转化产物，用于代谢途径研究
• 去氧皮质酮同位素内标检测——采用同位素标记内标校正基质效应，提高质谱检测准确度
• 去氧皮质酮游离浓度测定——测定未与蛋白结合的游离态去氧皮质酮浓度，反映生物活性水平
• 去氧皮质酮总浓度测定——测定包括结合态和游离态的去氧皮质酮总浓度，用于全面评估
• 交叉反应性评估——考察检测方法对去氧皮质酮结构类似物的交叉反应情况，确保特异性
• 去氧皮质酮溶液pH值检测——测定去氧皮质酮溶液制剂的酸碱度，确保制剂稳定性符合规范
• 去氧皮质酮水分含量测定——检测去氧皮质酮原料中的残留水分，影响储存稳定性和有效期
• 去氧皮质酮残留溶剂检测——检测生产过程中残留的有机溶剂，确保产品安全性符合药典要求
• 去氧皮质酮重金属检测——检测去氧皮质酮样品中的重金属残留，符合药典限量标准
• 去氧皮质酮微生物限度检测——评估去氧皮质酮制剂的微生物污染水平，确保卫生学合格
• 去氧皮质酮溶出度测试——考察去氧皮质酮固体制剂在规定溶出介质中的释放速率
• 去氧皮质酮含量均匀度检测——评估去氧皮质酮固体制剂中主药含量的均匀程度，保证用药安全

检测信息

去氧皮质酮检测是一种针对肾上腺皮质分泌的盐皮质激素——去氧皮质酮（DOC）进行定性定量分析的检测项目，应用于诊断辅助、药物质量控制、内分泌研究及食品安全等领域。

检测目的在于准确测定各类生物样本及药物制剂中去氧皮质酮的浓度水平，涉及的技术手段包括液相色谱-串联质谱法、气相色谱-质谱法、放射免疫分析法等，可满足血清、尿液、组织匀浆及原料药等多种基质样品的分析需求。

检测流程涵盖样品前处理（萃取、衍生化）、色谱分离、质谱检测及数据分析等环节，核心参数包括检出限、定量限、线性范围、回收率和精密度，确保检测结果满足药典及检验的规范要求。

常见问题

去氧皮质酮检测需要多长时间？

通常7-15个工作日，具体时间根据检测项目数量和样品类型确定，涉及代谢产物分析等复杂项目可能需要更长时间。

去氧皮质酮检测费用大概多少？

根据检测项目数量确定，不同检测方法如液质联用法、放射免疫法等的收费标准不同，具体费用需依据检测方案报价。

去氧皮质酮检测报告有什么用途？

可用于质量评估、项目验收、诊断辅助及药物质量控制等，北京中科光析科学技术研究所检测中心出具的检测报告具有社会公信力。

去氧皮质酮检测的样品采集有什么要求？

血清样品通常要求清晨空腹采集并避免溶血，尿液样品需收集24小时尿样并加入防腐剂，药物制剂样品需密封避光保存防止去氧皮质酮降解，具体采样要求可咨询检测方案。

总结

去氧皮质酮检测是对肾上腺皮质激素去氧皮质酮进行定性定量分析的检测项目，涵盖血清、尿液及药物制剂等样品的含量测定、纯度分析和有关物质检测。北京中科光析科学技术研究所检测中心检测周期通常7-15个工作日。